Altmetrics
Downloads
111
Views
44
Comments
0
A peer-reviewed article of this preprint also exists.
This version is not peer-reviewed
Submitted:
28 November 2023
Posted:
29 November 2023
You are already at the latest version
Biological model | Exposure compounds | Exposure conditions | Cellular and tissues damage | Impaired biochemical markers | References |
Chinese Hamsters |
Commercial formulation (550 g/L) |
AR: oral gavage T: 9 days C: 100 mg/kg of body weight |
NA | ND: Peroxissomes plorifaration | Vainio et al. (1982) [25] |
Rattus novergicus |
Commercial formulation (550 mg/kg) |
AR: oral gavage T: 2 weeks C: 100-200 mg/kg of body weight |
NA |
LM: peroxissome proliferation, CrAT, protein lipases AM: CAT |
Vainio et al. (1983) [26] |
Rattus novergicus |
Commercial formulation ( 550 g/L) |
AR.: intragastrically gavage T: 2 weeks C: 100, 150 and 200 mg/kg of body weight |
NA |
XM: EH, UDPglucuronosyltransferase , GST AM: GST |
Hietanen et al. (1983) [27] |
Rattus novergicus | Active ingredient |
AR: feeding T: 14 h C: 0.25% w/w |
NA |
LM: CrAT, palmitoyl-CoA, triglycerides AM: CAT |
Kawashima et al. (1984) [28] |
Rattus novergicus | not specified |
AR.: feeding T: 14 days C: 0.5 % of diet |
NA | LM: stearoyl-CoA | Kawashima et al. (1984) [29] |
Biological model | Exposure compounds | Exposure conditions | Cellular and tissues damage | Impaired biochemical markers | References |
Rattus novergicus | Active ingredient |
AR: feeding and subcutaneously T: 1 or 2 weeks C: 0.25% of diet or 0.93 mmole or 1.86 mmole per kg of body weight |
NA | LM: acyl-CoA hydrolase II; β oxidation | Katoh et al. (1984) [30] |
Rattus novergicus |
Commercial formulation ( 550 g/L ) |
AR: intragastrically ET: 14 days CT: 1 mmol/kg of body weight |
NA |
LM: peroxissome proliferation, β-oxidation AM: GR |
Hietanen et al. (1985) [31] |
Mus musculus | not specified |
AR: diet T: 4 days C: --- |
Increase liver somatic index |
LM: palmitoil-CoA, CrAT EM: cytochrome oxidase |
Lundgren et al. (1987) [32] |
Rattus novergicus | Active ingredient |
AR: gavage and feeding T: single dose and 13 days C: 553 mg/kg and 1090 mg/kg (single dose); 0, 15, 60, 100, or 150 mg/kg/day (13 days) |
Dose levels of 100 or 150 mg/kg/day produced minimal swelling and increased staining homogeneity in the liver cells and were associated with a slight elevation of liver weight |
LF: ALT, ALP EM: glucose |
Gorzinskj et al. (1987) [33] |
Biological model | Exposure compounds | Exposure conditions | Cellular and tissues damage | Impaired biochemical markers | References |
Mus musculus | not specified |
AR: feeding T: 4 days C: 100 mg/kg/bw |
NA |
XM: EH, CYP450, GST, peroxissome proliferation AM: GST |
Lundgren et al. (1987) [34] |
Rattus novergicus |
Active ingredient (>99%) |
AR.: intragastrically gavage T: 2 weeks C: 100 mg/kg of body weight |
NA | XM: peroxisome proliferation, CYP450, UDP-glucunorosyl transferase, NADPH diaphorase | Mustonen et al. (1989) [35] |
Rattus novergicus | Active ingredient |
AR.: feeding T: 7 months C: 0.05% of diet |
NA | LM: peroxissome proliferation, acyl Coa oxidase, dicarboxylyl CoA oxidase | Abdellatif et al.. (1990) [36] |
Mus musculus |
Active ingredient (97- 99%) |
AR.: oral intubathion T: 14 days exposure + 7 days recovery C: 50 mg/kg |
Increase liver/ body weight ratio | LF: ALT | Kuntz et al. (1990) [37] |
Rattus novergicus | Active ingredient |
AR: feeding T: 6 days C: 1.680 ppm |
NA |
LM: CrAT; carnitine palmitoyltransferase fatty acyl-CoA dehydrogenase cyanide-insensitive fatty acyl-CoA, peroxissome proliferation AM: CAT |
Kozuka (1991) [38] |
Biological model | Exposure compounds | Exposure conditions | Cellular and tissues damage | Impaired biochemical markers | References |
Rattus novergicus | not specified |
AR.: oral T: 2 weeks C: 200 mg/kg/day |
NA | XM: NADPH cytocrome C reductase, aniline hydroxylase, Cytocrome B, NADPH ferricicyanide reductase, aminopyrine N-demethylase | N Inomata et al. (1991) [39] |
Mus musculus |
Active ingredient (>97%) |
AR: oral intubation T: 7 days C: 50 mg/kg of body weight |
NA | XM: amidopyrine N-demethylas, Benzo [a]pyrene hydroxilase | Chaturvedi et al. (1991) [40] |
Rattus novergicus | Commercial formulation |
AR: oral and middorsal skin applications T: single dose C: 1.9 and 2.6 mg/kg of body weight |
NA | XM: CYP450, ethylmorphine N-demethylase, ethoxyresorufin O-deethylase | Knopp and Schiller (1992) [41] |
Rattus novergicus | not specified |
AR: oral T: single dose; 30 days and 180 days C: 600 mg/kg (single dose) and 200 ppm (30 and 180 days) |
NA |
LF: AST, ALT, ALP EM: LDH, amylase, glucose ND: Creatinine |
Paulino et al. (1996) [42] |
Mus musculus | Active ingredient |
AR.: feeding T: 4 days C: 0.125% of diet |
NA | LF: mdr2 gene | Miranda et al. (1997) [43] |
Biological model | Exposure compounds | Exposure conditions | Cellular and tissues damage | Impaired biochemical markers | References |
Rattus novergicus | Active ingredient |
AR: oral gavage T: single dose C: 375 mg/L |
NA | XM: CYP1A1, CYP1A2, CYP1B1 | Badawi et al. (2000) [44] |
Rattus novergicus |
Active ingredient (>98%) |
AR: injections T: 30 days C: 70 mg/kg of body weight |
NA | EM: mitochondrial dysfunction | Di Paolo et al. (2001) [45] |
Rattus novergicus ; Mus musculus and Syrian hamsters |
Active ingredient |
AR: feeding T: 3 months C: 0, 12, 28, 83, 250, 700, and 1,680 ppm (M. musculus); 0, 17, 83, 250, 750, 1,250, and 2,500 ppm (R. novergicus); 0, 12, 100, 500, 1,000, and 5,000 ppm (Syrian hamsters) |
Increase of mice liver weith |
XM: CYP450; peroxissome proliferation AM: CAT |
Ozaki et al. (2001) [46] |
Mus musculus | Active ingredient |
AR: feeding T: 6 days C: 1.680 ppm |
NA | ND: c-myc gene | Ge et al. (2002) [47] |
Mus musculus | Active ingredient |
AR: Intraperitoneally T: 55 days C: 3.8 mg/kg bw |
NA | EM: LDH, MDH | Yilmaz and Yuksel (2005) [48] |
Biological model | Exposure compounds | Exposure conditions | Cellular and tissues damage | Impaired biochemical markers | References |
Rattus novergicus | not specified |
AR: drink water T: 25 day C: 50 and 100 ppm |
NA |
AM: SOD, GSH, GR, MDA EM: LDH, creatine kinase LF: AST XM: GSH |
Celik et al. (2006) [49] |
Rattus novergicus | Active ingredient |
AR: Feed and drink water T: 30 days C: 25 ppm and 50 ppm (water) and 50 ppm and 100 ppm (food) |
No hepatic damage was observed, but the level of 2,4-D in the liver was found to be significantly higher in both the feed and water groups compared to the control group. | NA | Aydin et al. (2006) [50] |
Rattus novergicus | Active ingredient |
AR: drink water T: 21 days C: 600 ppm or 126 mg/kg |
Vascular congestion, cytoplasmic vacuolization, and mononuclear cells’ infiltration |
AM: SOD, CAT, GPx, MDA LF: AST, ALT, ALP, γ-glutamyl transpeptidase EM: LDH |
Troudi et al. (2012) [23] |
Rattus novergicus |
Commercial formulation (600 g/L) |
AR: oral gavage T: 4 weeks C: 5 mg/ kg/ bw |
NA |
AM: SOD, CAT, GPx, GR, MDA LF: AST, ALT, ALP, γ-GGT, total bilirubin. LM: change of fatty acid composition |
Nakbi. et al (2010) [51] |
Biological model | Exposure compounds | Exposure conditions | Cellular and tissues damage | Impaired biochemical markers | References |
Rattus novergicus |
Commercial formulation (600 g/L) |
AR: oral gavage T: 4 weeks C: 15, 75 and 150 mg/kg of body weight |
Body weight decreased and the liver weight increased significantly .2,4-D induced hepatic cord disruption, focal necrosis, vessel dilation and pycnotic nucleus. |
LF: AST, ALT, ALP, γ-GGT AM: CAT, GR |
Tayeb et al. (2010) [52] |
Rattus novergicus |
Commercial formulation (600 g/L) |
AR: oral gavage T: 4 weeks C: 5 mg/kg of body weight/ day |
Vascular congestion and wide sinusoidal spaces and a necrotic |
AM: SOD, CAT, GPx, MDA LF: AST, ALT LM: low density lipoprotein, cholesterol |
Nakbi et al. (2012) [53] |
Rattus novergicus |
Commercial formulation (600 g/L) |
AR: oral gavage T: 28 days C: 15, 75 and 150 mg/kg/bw/day |
NA |
AM: SOD, CAT, GPx, GR, MDA LM: change of fatty acid composition |
Tayeb et al. (2013) [54] |
Rattus novergicus | not specified |
AR: feeding T: 16 weeks C: 200 mg/kg/day |
2,4-D acid iso-octylester caused the formation of atypical cell foci (ACF) in the pancreata and livers of rats. | NA | Kalipici et al. (2013) [55] |
Biological model | Exposure compounds | Exposure conditions | Cellular and tissues damage | Impaired biochemical markers | References |
Rattus novergicus |
Active ingredient (≥ 90%) |
AR: oral gavage T: 19 days C: 100 mg/kg of body weight |
NA | AM: CAT, MDA, total antioxidant capacity | Mazhar. et al. (2014) [56] |
Rattus novergicus | Commercial formulation |
AR: oral T: 28 days C: 75 or 150 mg/kg of body weight |
2,4-D. increased liver weight and induced nuclear changes in liver cells, including alterations in size and shape, irregularity, and slight distention of nuclear envelope, Hepatic nuclei exhibited varying degrees of pyknosis, disaggregation and apoptosis. |
LF: AST, ALT, ALP, total bilirubin AM: GR, SOD EM: LDH |
Al-Baroudi et al. (2014) [57] |
Rattus novergicus | Commercial formulation |
AR: oral gavage T: 24 h (single dose) C: 639 mg/kg of body weight |
NA |
AM: hydroperoxyl and carbonyl lipids EM: glycogen |
Dakhakhni et al. (2016) [58] |
Mus musculus | Active ingredient |
AR: oral T: 45 days C: 30, 60, 90 mg/kg/day |
Vascular and hepatocellular lesions with necrotic changes and focal areas of necrosis in the liver |
AM: GSH, SOD, CAT, GPx, GR, GST and total –SH EM: ATP and SDH XM: GSH and GST |
Satapathy and Rao (2018) [59] |
Biological model | Exposure compounds | Exposure conditions | Cellular and tissues damage | Impaired biochemical markers | References |
Rattus novergicus | Active ingredient |
AR: oral gavage T: 4 weeks C: 150 mg/Kg/day |
NA |
AM: SOD, CAT, GSH, MDA LF: AST, ALT XM: GSH ND: Urea and creatinine |
Shafeeq and Mahboob (2020) [60] |
Rattus novergicus | Commercial formulation (806 g/L) |
AR: inhalation and feed T: 6 months C: 3.71/6.19 and 9.28×10−3 g a.i./ha |
The groups exposed to oral 2,4-D had a higher incidence of steatosis, and exposed to high doses had increased liver inflammation. | LF: ALT | Bonfim et al (2020) [61] |
Rattus novergicus |
Commercial formulation (600 g/L) |
AR: oral gavage T: 4 weeks C: 5 mg/kg/b.w./day |
Rat livers shown perivascular inflammatory infiltration around the vessel, sinusoidal dilatation and vacuolization of hepatocytes |
AM: SOD, CAT, GSH, GPx, GST, MDA LF: AST, ALT, ALP, total bilirubin EM: LDH XM: GST, GSH |
Tichati et al. (2020) [21] |
Rattus novergicus |
Active ingredient (> 98%) |
AR: cannulation of portal and cava veins liver T: 20 min. C: 10 – 400 µM |
Membrane lipid bilayer deformity | EM: NADH, NAD+ , lactate, glycolisis, gluconeogenesis | Salla et al. (2019) [62] |
Biological model | Exposure compounds | Exposure conditions | Cellular and tissues damage | Impaired biochemical markers | References |
Rattus novergicus | Active ingredient |
AR: oral gavage T: 4 weeks C: 150 mg/Kg/day |
NA |
AM: SOD, CAT, GSH, MDA LF: AST, ALT, ALP XM: GSH ND: urea and creatinine |
Shafeeq and Mahboob (2021) [63] |
Rattus novergicus |
Commercial formulation (600 g/L) |
AR: oral gavage T: 30 days C: 5 mg/kg/b.w |
2,4-D increases relative and absolute liver weights. Furthermore, 2,4-D induces severe infiltration of mononuclear inflammatory cells with vacuolar degeneration around a dilated central lobular vein, congestion of the hepatic sinusoids, and degenerative hepatocytes with largely vacuolated cytoplasm and a large number of lipid droplets. | AM: SOD, CAT, GPx, GST, MDA, carbonyl proteins LF: AST, ALT, ALP, γ-GGT EM: LDH XM: GST, GSH |
Tichati et al. (2021) [22] |
Biological model | Exposure compounds | Exposure conditions | Cellular and tissues damage | Impaired biochemical markers | References |
Rattus novergicus |
Commercial formulation (480 g/L) |
AR: oral T: 60 days C: 5 mg/kg of body weight |
In the liver tissue of rats, focal areas of mononuclear cell infiltration in the pericentral and periacinal region, sinusoidal dilatation, and hyperemia in the vessels and areas of pyknosis and parenchymal degeneration in the nuclei of hepatocytes were determined |
LF: AST, ALT, ALP AM: SOD, GSH, CAT, MDA XM: GSH ND: NF-κB, COX-2, TNF-α, MCP-I, TGFβI, and CYP2E P53, Bax/Bcl-2, caspase-3, caspase-8, caspase-9, and PARP |
Sinan Ince et al. (2022) [64] |
Rattus novergicus | 2,4-D, gliphosate and dicamba (not specified) |
AR: drink water T: 90 days C: gliphosate (0.5 mg/kg bw/day) + 2,4-D (0.3 mg/kg bw/day) + dicamba (0.02 mg/kg bw/ day) |
NA | AM: GSH and MDA | Nechalioti et al. (2023) [65] |
Ictalurus punctatus |
Active ingredient 2,4-D (>99%) Picloram (>99%) |
AR: water expossure T: 10 days C: 22.5, 7.5, and 2.25 mg/L |
NA | XM: ethoxyresorufin 0-deethylase | Gallagher and Digiulio (1991) [66] |
Biological model | Exposure compounds | Exposure conditions | Cellular and tissues damage | Impaired biochemical markers | References |
Cyprinus carpio |
Active ingredient (>98%) |
AR: water exposure T: 96 h and 14 days C: 310, 295 and 270 mg/L (96 h ) 150, 200, and 250 mg/L (14 days) |
Hepatocycites shown slight vacuolar degeneration and pycnotic nuclei (some of them displaced) | LF: AST, ALT | Neskovic et al. (1994) [67] |
Oreochromis niloticus |
Commercial formulation (500 g/L) |
AR: water exposure T: 96 h C: 27 ppm |
NA |
AM: SOD, GPx, GR EM: glucose-6-phosphate dehydrogenase |
Oruç. and Uner (2000) [68] |
Fundulus heteroclitus | not specified |
AR: water expossure T: 21 days C: 0.04, 0.41, and 4.1 µM |
NA | ND: peroxissome proliferation | Ackers et al. (2000) [69] |
Cyprinus carpio |
Commercial formulation (500 g/L) |
AR: water exposure T: 96 h C: 87 ppm |
NA | AM: GST, SOD EM: G6PD XM: GST |
Oruç and Uner (2002) [70] |
Leporinus obtusidens |
Commercial formulation (868 g/L) |
AR: water exposure T: 96 h C: 1 and 10 mg/L |
NA | EM: glycogen, lactate, glucose | Fonseca et al. (2008) [71] |
Rhamdia quelen |
Commercial formulation (720 g/L ) |
AR: water exposure T: 96 h C: 0, 400, 600 and 700 mg/L |
Hepatocytes vacualization and changes in its arrangement cords | EM: glycogen,lactate, glucose | Cattaneo et al. (2008) [72] |
Carassius auratus | Active ingredient |
AR: water exposure T: 90 h C: 1, 10 and 100 mg/L |
NA | AM: carbonyl proteins, lipid peroxidases LM: lipid peroxidases |
Matviishyn et al. (2014) [73] |
Poecilia vivipara | Commercial formulation (868g/L) |
AR: water exposure T: 48 h C: 10,20 and 40μl |
Swollen nuclei and cytoplasmic vacuolization. Finally, the 40 μl/L group presented blood vessel alterations indicating vasodilatation, hepatocytes with swollen nuclei, Ito cells, and micronuclei. | NA | Vigário and Sabóia-Morais (2014) [74] |
Rhamdia quelen |
Commercial formulation (720 g/L) |
AR: water exposure T: 90 days C: 0.5 and 2 mg/L |
NA |
AM: CAT, MDA EM: glycogen; lactate, glucose |
Menezes. et al. (2015) [75] |
Cyprinus carpio L | not specified |
A.R.: water exposure T: --- C: 0.2 mg/dm3 |
NA | EM: ICDH, LDH, G6PD | Yakovenko et al. (2018) [76] |
Biological model | Exposure compounds | Exposure conditions | Cellular and tissues damage | Impaired biochemical markers | References |
Capoeta capoeta | not specified |
AR: water expossure T: 7 days C: 10 and 20 mg/L |
NA |
AM: plasma oxidative status index LF: AST |
Kaya et al. (2018) [77] |
Danio rerio |
Active ingredient (> 97%) |
AR: water exposure T: 48 h C: 2.5, 5 and 10 mg/L |
Hepatocytes had heterogeneous eosiniphilic, cytosol vacualization and cell nucleus were eccentric, Loss of cell boundaries and liver with necrotic appearence, Release of cytosolic content among adjacent cells |
LF: AST, ALT, ALP AM: CAT, GST XM: GST EM: LDH |
Martins et al. (2021) [2] |
Triturus cristatus carnifex | Commercial formulation (37% of 2,4-D as iso-octylic ester) | AR: water exposure T: 3 months C: 25, 50, 75, 100, 125, and 150 ppm |
Vacuolar degeneration of liver parenchyma and necrosis of kidney tubules | NA | Zaffaroni et al. (1986) [78] |
Lithobates clamitans |
Active ingredient (>98%) |
AR: soil exposition T: 2 days C: 14.3 µg/cm² |
NA | NA | Van Meter et al. (2018) [79] |
Biological model | Exposure compounds | Exposure conditions | Cellular and tissues damage | Impaired biochemical markers | References |
Physalaemus albonotatus | Commercial formulation) (48.5% w/v of active ingredient) | AR: water exposure T: 96 h (acute) and 49 days (chronic) C: 350, 700, 1400, and 2400 mg/L(acute); 43.7, 87.5, 175 or 262.5 mg/L (chronic) |
The liver of treated tadpoles showed enlargement of hepatic sinu- soids , hypervascularization, dilation of blood vessels, and vacuolization of hepatocytes | NA | Curi et al. (2019) [80] |
Biological model | Exposure compounds | Exposure conditions | Impaired biochemical markers | References |
Liver GST of Rattus novergicus | Active ingredient |
AR.: enzyme kinetics T: --- C:--- |
AM: GST XM: GST |
Dierickx (1983) [81] |
Liver GST of Rattus novergicus |
Active ingredient (>99%) |
AR: enzyme kinetics T: --- C: 2 -12 mM |
XM: GST AM: GST |
Vessey and Boyer (1984) [82] |
Liver GST of Salmo gairdneri | Active ingredient |
AR: enzyme kinetics T: --- C: 2 mM |
AM: GST XM: GST |
Dierick (1985) [83] |
Liver GST of Homo sapiens (autopsy) |
Active ingredient (>97%) |
AR: --- T: --- C: --- |
AM: GST XM: GST |
Singh (1985) [84] |
Liver GST of Cyprinus carpio | not specified |
AR: cell culture T: --- C: --- |
AM: GST XM: GST |
Elia et al. (2000) [85] |
Biological model | Exposure compounds | Exposure conditions | Impaired biochemical markers | References |
Liver GST of Rattus novergicus | not specified |
AR: --- T: --- C: --- |
AM: GST XM: GST |
Dierickx (1988) [86] |
Liver GST of Chalcalburnus tarichii Pallas |
Active ingredient |
AR.: --- T: --- C: 0.6, 0.23 and 0.57 mM |
AM: GST XM: GST |
Özaslan et al. (2018) [87] |
Liver mitochondria of Rattus novergicus | Active ingredient |
AR.: cell culture T: --- C: 0, 0.2, 0.5, 1.0, and 2 mM. |
LM: palmitoyl CoA hydrolase , fatty acyl CoA EM: mitochondrial dysfunction |
Dixon et al. (1990) [88] |
Liver mitochondria of Rattus novergicus | not specified |
AR: cell culture T: --- C: 0.1 - 4.0 mM |
EM: mitochondrial dysfunction | Zychlinski and Zolnierowicz (1990) [89] |
Liver mitochondria of Rattus novergicus | Active ingredient |
AR: cell culture T: --- C: 100, 200, 300, 400, 500, 600, 700 and 800 µM |
EM: SDH, cytochrome c reductase, mitochondrial dysfunction | Palmeira et al. (1994) [90] |
Biological model | Exposure compounds | Exposure conditions | Impaired biochemical markers | References |
Liver mitochondria of Rattus novergicus | Commercial formulation (2,4-D 1.08 M + Picloram 0.265 M) |
AR: cell culture T: --- C: 66.2 nmol picloram + 270 nmol 2,4-D mg-1 protein |
EM: NADH oxidase, NADH cytochrome c reductase, ATP, mitochondrial dysfunction | Pereira et al. (1994) [91] |
Liver mitochondria of Rattus novergicus | Commercial formulation. Tordon (2,4-D 300 g/L + picloram 75 g/L) |
AR.: cell culture T: --- C: --- |
EM: mitochondrial dysfunction | Oakes and Pollak (1999) [92] |
Liver Rattus novergicus mitochondria |
Active ingredient (>98%) |
AR: injections T: 30 days C: 70 mg/kg of body weight |
EM: mitochondrial dysfunction | Di Paolo et al. (2001) [45] |
Hepatocytes of Rattus novergicus | Active ingredient |
AR: cell culture T: --- C: 1-10 mM |
EM: LDH, ATP, ADP, AMP, NADH, NAD+ AM: GSH, GSSG XM: GSH, GSSG |
Palmeira et al. (1994) [93] |
Biological model | Exposure compounds | Exposure conditions | Impaired biochemical markers | References |
Hepatocytes of Rattus novergicus |
Active ingredient (> 98%) |
AR: cell culture T: 200 min C: 1, 5 and 10 mM |
AM: MDA, proteins thiol, GSH XM: GSH |
Palmeira et al. (1995) [94] |
Hepatocytes of Rattus novergicus | Active ingredient |
AR: cell culture ET: 3 months C.T: 1 mM |
NA | Li et al. (2003) [95] |
Hepatocytes of Metynnis roosevelti | Active ingredient |
AR: cell culture T: --- C: 0.275, 2.75 and 27.5 mg/L |
EM: mitochondrial dysfunction | Salvo et al. (2015) [96] |
HepG2 cells | Active ingredient |
AR: cell culture T: 48 h C: 4, 8 and 16 mM |
EM: mitochondrial dysfunction ND: Cell cicle alterations, apoptose, DNA damage |
Tuschl and Schwab (2003) [97] |
HepG2 cells | Active ingredient |
AR: cell culture T: 48 h C: 8, 14 and 16 mM |
ND: Cell cycle alterations, apoptosis, DNA damage | Tuschl and Schwab (2004) [98] |
Biological model | Exposure compounds | Exposure conditions | Impaired biochemical markers | References |
HepG2 cells | Commercial formulation |
AR: cell culture T: --- C: 0.1 nM to 4 mM |
ND: Genes involved to stress response, cell cycle control, immunological and DNA repair genes. (FTH1, FTL, PCNA, DCLRE1C, TCLK1, JM11, VEGF, USP19, DDB2, IL1RL1, PTGER3 and GTF2A. | Bharadwaj et al. (2005) [99] |
HepG2 cell |
Active ingredient (>90%) |
AR.: cell culture T: --- C: 0.001 - 0.1 mM |
NA | Barrón Cuenca et al. (2022) [100] |
Liver homogenates of Rattus novergicus | Active ingredient |
AR: cell culture T: --- C: --- |
LM: cholesterol | Olson et al. (1974) [101] |
Biological model | Exposure compounds | Exposure conditions | Impaired biochemical markers | References |
Chicken embryo |
Commercial formulation (37%) |
AR.: injected into the air cell of the eggs T: 19 days C: 1, 2 and 4 mg/egg |
XM: ethoxycoumarin O-deethylase, GST AM: GST |
Santagostino et al. (1991) [102] |
Chicken Liver |
Commercial formulation (31.6% w/v) |
AR: Fertilized eggs were externally treated T: 21 days C: 3.1 mg |
EM: G6Pase LM: total lipids AM: CAT |
Duffard et al. (1993) [103] |
Biological model | Hepatoprotective agent | Concentrations and time of exposure | Hepatoprotective effects | References |
Rattus novergicus | Extra virgin olive oil (EVOO) and its hydrophilic fraction (OOHF) | C: 2,4-D (5 mg/kg body weight) + EVOO (300 μl/day) or OOHF (1 mL/day) T: 4 weeks |
EVOO and OOHF suplementation induced a significant increase in the antioxidant enzyme activities (SOD, CAT, GPx and GR), liver marker (AST, ALT and total bilirubin) and a decrease in the conjugated dienes (CD) and thiobarbituric acid-reactive substances (TBARs) levels in the liver. | Nakbi, A. et al. (2010) [51] |
Rattus novergicus | Extra virgin olive oil (EVOO) and its hydrophilic fraction (OOHF) | C: 2,4-D (5 mg/kg body weight) + EVOO (300 μl/day) or OOHF (1 mL/day) T: 4 weeks |
EVOO and OOHF suplementation induced a significant increase in the antioxidant enzyme activities (SOD, CAT, GPx), liver marker (AST, ALT and total bilirubin), and decreased MDA levels in the liver. | Nakbi, A. et al. (2012) [53] |
Biological model | Hepatoprotective agent | Concentrations and time of exposure | Hepatoprotective effects | References |
Rattus novergicus | Chamomile capitula extract | C: 2,4-D (75 or 150 mg/kg body weight) + Chamomile capitula extract- (500 mg/kg body weight) T: 28 days |
Chamomile capitula extract presented antioxidant effects, improving the levels of SOD and GR. The levels of hepatic enzymes AST, ALT, ALP, and LDH decreased, as well as total bilirubin. Additionally, the degenerative damages in the hepatic tissue caused by 2,4-D were also alleviated. | Al-Baroudi et al. (2014) [57] |
Mus musculus | Curcumin | C: 2,4-D (30, 60, 90 mg/kg/day) + Curcumin (10 mg/kg/day) T: 45 days |
Curcumin supplementation exhibited antioxidant effects, mainly normalizing the levels of GSH, GR, and lipid peroxidation. Furthermore, curcumin supplementation reduced hepatic tissue damage. | Satapathy and Rao (2018) [59] |
Biological model | Hepatoprotective agent | Concentrations and time of exposure | Hepatoprotective effects | References |
Rattus novergicus | Magnesium (Mg) | C: 2,4-D (150 mg/kg body weight/day) + Mg supplement (50 mg/kg body weight/day) T: 4 weeks |
Mg supplementation exhibited its antioxidant properties by significantly improving urea, creatinine SOD, MDA, CAT, GSH and MDA levels and antioxidant enzyme activities. Hepatic markers were also improved: AST, ALT and ALP and absolute liver weight. | Shafeeq and Mahboob (2020) [60] |
Rattus novergicus | Selenium (Se) | C: 2,4-D (5 mg/kg body weight/day) + Se supplement (1 mg/kg body weight/day) T: 4 weeks |
Se supplementation in 2,4- D-treated rats elicited a reduction in the toxic effects of the pesticide by improving the studied parameters (absolute liver weight, total bilirubin, AST, ALP, LDH, MDA and carbonyl proteins) which was confirmed by the histological study of the liver. | Tichati, L. et al. (2020) [21] |
Rattus novergicus | Selenium (Se) | C: 2,4-D (150 mg/kg body weight/day) + Se supplement (1 mg/kg body weight/day) T: 4 weeks |
Se supplementation exhibited its antioxidant properties by significantly improving urea, creatinine, ALP, AST, and ALT, and MDA levels and antioxidant enzyme activities. Hepatic and renal toxicities were attenuated by Se supplementation. | Shafeeq and Mahboob (2021) [63] |
Biological model | Hepatoprotective agent | Concentrations and time of exposure | Hepatoprotective effects | References |
Rattus novergicus | Thymus munbyanus extract (AETM) | C: 2,4-D (5 mg/kg body weight) + AETM (10 ml/kg body weight) T: 30 days |
AETM supplementation showed a marked enhancement in the above altered hepatic functional and antioxidant parameters (CAT, GST, total bilirubin, AST, ALP, MDA, carbonyl proteins) and liver histopathology. | Tichati, L. et al. (2021) [22] |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 MDPI (Basel, Switzerland) unless otherwise stated